Evidence map›Paper›PMID 26776231›Full record

ReviewAdvanced drug delivery reviews2016

Nanotechnology inspired tools for mitochondrial dysfunction related diseases.

Ru Wen, Bhabatosh Banik, Rakesh K Pathak, Anil Kumar, Nagesh Kolishetti, Shanta Dhar

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ru WenNanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, United States.
Bhabatosh BanikNanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, United States.
Rakesh K PathakNanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, United States.
Anil KumarNanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, United States.
Nagesh KolishettiNanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, United States; Partikula LLC, Sunrise, FL 33326, United States.
Shanta DharNanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, United States. Electronic address: shanta@uga.edu.

Funding

Combined Nanoparticle and Neural Stem Cell Therapies in a Pig Model of StrokeR01NS093314 · NINDS · UNIVERSITY OF GEORGIA · PI WEST, FRANKLIN D · 2015 to 2019
$2.4M
A high-density lipoprotein-based theranostic nanoparticle platform for atherosclerosisR56HL121392 · NHLBI · UNIVERSITY OF GEORGIA · PI DHAR, SHANTA · 2014 to 2014
$364k
NHLBI NIH HHS R56 HL121392NHLBI NIH HHS R56HL121392NINDS NIH HHS R01 NS093314NINDS NIH HHS R01NS093314
6 · The paper itself

Abstract

Mitochondrial dysfunctions are recognized as major factors for various diseases including cancer, cardiovascular diseases, diabetes, neurological disorders, and a group of diseases so called "mitochondrial dysfunction related diseases". One of the major hurdles to gain therapeutic efficiency in diseases where the targets are located in the mitochondria is the accessibility of the targets in this compartmentalized organelle that imposes barriers toward internalization of ions and molecules. Over the time, different tools and techniques were developed to improve therapeutic index for mitochondria acting drugs. Nanotechnology has unfolded as one of the logical and encouraging tools for delivery of therapeutics in controlled and targeted manner simultaneously reducing side effects from drug overdose. Tailor-made nanomedicine based therapeutics can be an excellent tool in the toolbox for diseases associated with mitochondrial dysfunctions. In this review, we present an extensive coverage of possible therapeutic targets in different compartments of mitochondria for cancer, cardiovascular, and mitochondrial dysfunction related diseases.

Indexed as

NanotechnologyAnimalsCardiovascular DiseasesHumansMitochondriaMitochondrial DiseasesNeoplasmsNervous System Diseases

Identifiers

PMID26776231
PMCPMC4798867

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.